Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Identifying and characterizing molecules with antifungal activity to combat Candida albicans

FY 2023-24

Summary
Although largely overlooked, fungi cause deadly systemic infections in a growing population of immunocompromised patients, leading to approximately 1.5 million deaths annually. The current incidence of fungal infections is largely attributed to increases in invasive medical procedures, the use of high-dose corticosteroids, solid organ transplantation, infection with HIV-1, as well as the widespread use of broad-spectrum antimicrobials. Candida albicans is a leading cause of these infections with mortality rates of ~40%. Currently, there are only three major classes of drugs used to treat systemic fungal infections: azoles, polyenes, and echinocandins. The growing population of immunocompromised individuals and the emergence of drug-resistant fungi now threatens global public health. In recent years, drug repurposing has emerged as a promising strategy for the expedited development of novel therapeutics against neglected pathogens. In a quest to identify novel antifungal therapies, I screened the Medicines for Malaria Venture's (MMV) library of 640 compounds in various stages of drug development for activity against C. albicans. Through this approach, I identified 28 molecules that displayed reproducible antifungal activity. My future work will include: 1) assessing whether these compounds have activity against other fungal pathogens; 2) determining the mechanisms of action of prioritized compounds using a variety of genomic approaches; and 3) assessing hit compounds therapeutic potential by evaluating toxicity against human cells, in vitro metabolic stability, as well as efficacy in mouse models of systemic candidiasis. My project will reveal much-needed novel therapeutic strategies to combat rising fungal pathogens that threaten thousands of lives around the globe.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
496519
Name
Fallah Sara
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Identifying and characterizing molecules with antifungal activity to combat Candida albicans
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Antifungal Drug Discovery; Antimicrobial Resistance; Dose Response Assays; Fungal Genetics; Small Molecule Library Screening
Abstract
Although largely overlooked, fungi cause deadly systemic infections in a growing population of immunocompromised patients, leading to approximately 1.5 million deaths annually. The current incidence of fungal infections is largely attributed to increases in invasive medical procedures, the use of high-dose corticosteroids, solid organ transplantation, infection with HIV-1, as well as the widespread use of broad-spectrum antimicrobials. Candida albicans is a leading cause of these infections with mortality rates of ~40%. Currently, there are only three major classes of drugs used to treat systemic fungal infections: azoles, polyenes, and echinocandins. The growing population of immunocompromised individuals and the emergence of drug-resistant fungi now threatens global public health. In recent years, drug repurposing has emerged as a promising strategy for the expedited development of novel therapeutics against neglected pathogens. In a quest to identify novel antifungal therapies, I screened the Medicines for Malaria Venture's (MMV) library of 640 compounds in various stages of drug development for activity against C. albicans. Through this approach, I identified 28 molecules that displayed reproducible antifungal activity. My future work will include: 1) assessing whether these compounds have activity against other fungal pathogens; 2) determining the mechanisms of action of prioritized compounds using a variety of genomic approaches; and 3) assessing hit compounds therapeutic potential by evaluating toxicity against human cells, in vitro metabolic stability, as well as efficacy in mouse models of systemic candidiasis. My project will reveal much-needed novel therapeutic strategies to combat rising fungal pathogens that threaten thousands of lives around the globe.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Fallah, Sara
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~